文献速递炎症性肠病

克罗恩病中阿达木单抗药物水平在周期间及周期内的患者内变异性

Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-02-27

这项前瞻性观察研究纳入19例接受阿达木单抗维持治疗的成人克罗恩病患者,在两个连续双周周期内按预定时间点(第4-6天、第7-9天、谷浓度第13-14天)重复测定药物水平,共111次评估。结果显示患者内药物水平在周期间无差异,前9天水平稳定后降至谷浓度,前9天获得的≥4.9 μg/mL水平可较有把握地预测治疗性谷浓度。

要点

  • 阿达木单抗谷浓度监测应在谷时进行,但前9天药物水平≥4.9 μg/mL可预测治疗性谷浓度。
  • 患者内药物水平在两个连续双周周期之间无显著差异,且不受疾病活动影响。
  • 药物水平在前9天稳定,随后从第1次或第2次访视至谷浓度平均分别下降1.06和0.89 μg/mL。

核心结论

  • 虽然治疗药物监测应在谷浓度时进行,但在前9天获得的药物水平≥4.9 μg/mL能以合理的置信度预测治疗性谷浓度。

研究设计与样本

  • 前瞻性观察研究,纳入19例已建立阿达木单抗维持治疗的成人克罗恩病患者,在两个连续双周周期内按预定时间点重复测定药物水平,共111次评估。

主要发现

  • 周期间配对访视的平均患者内药物水平无差异:第1次访视周期1为4.81 μg/mL vs 周期2为5.21 μg/mL(P=0.24),第2次访视周期1为4.86 μg/mL vs 周期2为4.82 μg/mL(P=0.91),谷浓度周期1为3.95 μg/mL vs 周期2为3.95 μg/mL(P=0.99)。
  • 药物水平在前9天(第1-2次访视)稳定,但从第1次或第2次访视至谷浓度平均分别下降1.06和0.89 μg/mL(P<0.001)。
  • 使用非时间因素(吸烟、注射器输送装置)和早期访视水平的模型解释了谷浓度变异的66-80%。
  • 受试者工作特征曲线分析中,前9天识别的预测治疗性谷浓度的阈值与谷浓度阈值本身相似,敏感性高但特异性中等。

关键数值与推荐

  • 本分析中,谷浓度≥4.9 μg/mL被视为治疗性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether therapeutic drug monitoring for adalimumab needs to be performed at trough has not been defined. AIM: To determine intra-patient adalimumab drug-level variation and to identify modulating patient and disease factors. METHODS: In this prospective observational study, adult patients with Crohn's disease established on maintenance adalimumab had drug levels measured repeatedly according to pre-defined schedules (visit 1: day 4-6, visit 2: day 7-9, trough: day 13-14) across two consecutive fortnightly cycles. Disease activity was assessed using Harvey-Bradshaw Index, C-reactive protein and faecal calprotectin. For this analysis, trough levels ≥4.9 μg/mL were considered therapeutic. RESULTS: Nineteen patients underwent 111 evaluations. Mean intra-patient drug levels from paired visits between cycles did not differ (visit1 cycle1: 4.81, cycle2: 5.21 μg/mL, P = 0.24, visit2 cycle1: 4.86, cycle2: 4.82, P = 0.91 and trough cycle1: 3.95, cycle2: 3.95, P = 0.99), irrespective of disease activity. Drug levels were stable over the first 9 days (visit 1-2), but declined to trough by a mean 1.06 and 0.89 μg/mL between visit 1 or 2, respectively (P < 0.001). Models using nontemporal factors (smoking, syringe delivery device) and levels at earlier visits accounted for 66-80% of the variance in trough levels. On receiver-operating curve analysis, thresholds identified in the first 9 days that predicted a therapeutic trough level were similar to the trough threshold itself, with high sensitivity but modest specificity. CONCLUSION: While therapeutic drug monitoring should be performed at trough, a drug level ≥4.9 μg/mL obtained during the first 9 days predicts a therapeutic trough drug level with reasonable confidence.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ward MG, Thwaites PA, Beswick L, et al. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther. 2017. PMID: 28239869. doi:10.1111/apt.13992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。